Skip to content

A randomized controlled trial of topical timolol plus standard wound care versus standard wound care alone on wound healing outcomes in patients with skin cancer undergoing Mohs micrographic surgery

A randomized controlled trial of topical timolol plus standard wound care versus standard wound care alone on wound healing outcomes in patients with skin cancer undergoing Mohs micrographic surgery

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20260701008
Enrollment
42
Registered
2026-07-01
Start date
2025-12-15
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-surgical wound erythema, pain, suture removal day and scar Topical 0.5% timolol maleate ophthalmic solution, Mohs surgery

Interventions

Apply 1 drop of 0.5% timolol maleate ophthalmic solution per 2 cm of surgical wound length, apply immediately after surgery, on days 2, 4 or 5, 7, and 14 (In patients whose sutures are completely remo
Active Comparator Drug,Placebo Comparator Drug
Topical 0.5% timolol maleate ophthalmic solution,Standard wound care

Sponsors

Dermatology department, Faculty of Medicine Ramathibodi Hospital, Mahidol University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age 18 years or older 2. Participants who are expected to be able to comply with the study protocol 3. Diagnosed with basal cell carcinoma, squamous cell carcinoma, or Bowen disease of the face, neck, scalp, or ears, and undergoing treatment with Mohs micrographic surgery 4. Postoperative wound size between 1 and 10 centimeters

Exclusion criteria

Exclusion criteria: 1. History of easily keloid scar formation 2. Taking immunosuppressive medications such as prednisolone, methotrexate, azathioprine, or rituximab 3. Has a blood clotting disorder 4. Has underlying medical conditions such as asthma, chronic obstructive pulmonary disease, second or third degree heart block, congestive heart failure, or stage 4 or 5 chronic kidney disease 5. Has underlying medical conditions that may affect wound healing, such as uncontrolled type 2 diabetes mellitus, systemic lupus erythematosus 6. Previous chemotherapy or radiation therapy to the facial area 7. Pregnancy or breastfeeding 8. Allergy to timolol 9. Has bradycardia 10. Has a neurological condition that impairs the ability to make a decision

Design outcomes

Primary

MeasureTime frame
Postsurgical wound erythema Days 4 or 5, day 7, and day 14 Erythema index by Colorimeter Derma-spectrometer(DSM) III

Secondary

MeasureTime frame
Postsurgical wound erythema Days 4 or 5, day 7, and day 14 Clinician erythema assessment scale (CEA), Antera3D ,Postsurgical pain Days 2, day 4 or 5, day 7, and day 14 Visual analogue scale ,Re-epithelialization Day 7 or day 14 Suture removal day without wound dehiscence,Postsurgical scar Day 42 Patient and Observer Scar Assessment Scale (POSAS)

Countries

Thailand

Contacts

Public ContactNatthachat Jurairattanaporn

Dermatology department, Faculty of Medicine Ramathibodi Hospital, Mahidol University

skin1465@hotmail.com0626425261

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026